Literature DB >> 728326

Platelet aggregation and chlorpromazine therapy.

D J Boullin, J M Know, J R Peters, M W Orr, M G Gelder, D G Grahame-Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 728326      PMCID： PMC1429706          DOI： 10.1111/j.1365-2125.1978.tb00881.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  5 in total

1.  Characterization of receptors mediating 5-hydroxytryptamine- and catecholamine-induced platelet aggregation, assessed by the actions of alpha- and beta-blockers, butyrophenones, 5-HT antagonists and chlorpromazine.

Authors:  D J Boullin; P A Glenton
Journal:  Br J Pharmacol       Date:  1978-04       Impact factor: 8.739

2.  Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine.

Authors:  D J Boullin; H F Woods; R P Grimes; D G Grahame-Smith
Journal:  Br J Clin Pharmacol       Date:  1975-02       Impact factor: 4.335

3.  The biochemical high-risk paradigm: behavioral and familial correlates of low platelet monoamine oxidase activity.

Authors:  M S Buchsbaum; R D Coursey; D L Murphy
Journal:  Science       Date:  1976-10-15       Impact factor: 47.728

4.  The ralationship between changes in 5-HT induced platelet aggregation and clinical state in patients treated with fluphenazine.

Authors:  M W Orr; D J Boullin
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

5.  Plasma noradrenaline and adrenaline concentrations and dopamine-beta-hydroxylase activity in patients with shock due to septicaemia, trauma and haemorrhage.

Authors:  C R Benedict; D G Grahame-Smith
Journal:  Q J Med       Date:  1978-01
  5 in total
  8 in total

Review 1.  Antipsychotic-induced venous thromboembolism: a review of the evidence.

Authors:  Staffan Hägg; Olav Spigset
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

2.  The reliability of 5-hydroxytryptamine induced platelet aggregation responses in schizophrenic patients treated with neuroleptic drugs.

Authors:  J M Knox; M W Orr; R Allen; M G Gelder; D G Grahame-Smith
Journal:  Br J Clin Pharmacol       Date:  1981-03       Impact factor: 4.335

Review 3.  Assessment of anti-psychotic drugs.

Authors:  A V Mackay
Journal:  Br J Clin Pharmacol       Date:  1981-03       Impact factor: 4.335

4.  Platelet shape change in patients with psychiatric disorders and treated with phenothiazines, thioxanthines, butyrophenones, benzodiazepines, tricyclic antidepressants and beta-adrenergic blocking agents.

Authors:  D J Boullin
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

5.  The effects of neuroleptic drugs on 5-hydroxytryptamine induced platelet aggregation in schizophrenic patients.

Authors:  M W Orr; J M Knox; R Allen; M G Gelder; D G Grahame-Smith
Journal:  Br J Clin Pharmacol       Date:  1981-03       Impact factor: 4.335

6.  Human platelet function as a model for investigating the clinical efficacy of chlorpromazine.

Authors:  M B Youdim; A Hefez; B Oppenheim
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

7.  Increased platelet membrane [3H]-LSD binding in patients on chronic neuroleptic treatment.

Authors:  M Schächter; D P Geaney; D G Grahame-Smith; P J Cowen; J M Elliott
Journal:  Br J Clin Pharmacol       Date:  1985-04       Impact factor: 4.335

Review 8.  Human platelet 5-hydroxytryptamine receptors: binding of [3H]-lysergic acid diethylamide (LSD). Effects of chronic neuroleptic and antidepressant drug administration.

Authors:  D G Grahame-Smith; D P Geaney; M Schachter; J M Elliott
Journal:  Experientia       Date:  1988-02-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.